"Combinations of plasma cfDNA concentration, integrity and tumor markers are promising biomarkers for early diagnosis of non-small cell lung cancer"

作者全名："Ren, Sai; Zeng, Guichuan; Yi, Yuling; Liu, Ling; Tu, Hongmei; Chai, Tingjia; Hu, Liyi"

作者地址："[Ren, Sai; Yi, Yuling; Liu, Ling; Tu, Hongmei; Hu, Liyi] Peoples Hosp Chongqing Liang Jiang New Area, Dept Lab Med, Chongqing, Peoples R China; [Zeng, Guichuan] Jian She Hosp, Dept Ultrasound, Chongqing, Peoples R China; [Chai, Tingjia] Chongqing Med Univ, Affiliated Hosp 2, Endocrine Lab, Chongqing, Peoples R China"

通信作者："Hu, LY (通讯作者)，Peoples Hosp Chongqing Liang Jiang New Area, Dept Lab Med, Chongqing, Peoples R China."

来源：HELIYON

ESI学科分类：　

WOS号：WOS:001110889100001

JCR分区：Q1

影响因子：3.4

年份：2023

卷号：9

期号：10

开始页：　

结束页：　

文献类型：Article

关键词：Plasma cfDNA; DNA integrity; ALU repeated sequence; Quantitative real -time PCR; Non -small cell lung cancer

摘要："Background: Circulating cell-free DNA (cfDNA) concentration and integrity as noninvasive bio-markers play an important role in cancer diagnosis, prognosis and therapy monitoring. However, few studies have been conducted on the combination of plasma cfDNA concentration, integrity and tumor markers (CEA, CA125, NSE and CYFRA21-1) for cancer detection. Thus, the purpose of this study was to investigate the diagnostic value of combining plasma cfDNA concentration, integrity and tumor markers in early detection of non-small cell lung cancer (NSCLC).Methods: Plasma cfDNA concentration from 50 healthy controls and 84 NSCLC patients were assessed by quantitative real-time PCR of ALU repeated sequence. Plasma cfDNA integrity was calculated as the ratio of long to short fragments (ALU115/60).Results: Plasma cfDNA concentration (ALU60 and ALU115) and integrity ALU115/60 were significantly higher in NSCLC patients with stage III/IV than in healthy controls (p = 0.0002, p < 0.0001, and p = 0.0093, respectively). The receiver operating characteristic (ROC) curve for discriminating NSCLC patients from healthy controls had an area under the curve (AUC) of 0.936 (95 % CI, 0.939-0.996). Moreover, the combination of plasma cfDNA concentration, integrity and tumor markers (CEA, CA125, NSE and CYFRA21-1) had higher diagnostic performance than either plasma cfDNA concentration alone, integrity alone or tumor markers alone, with sensitivity, specificity and AUC value of 94.05%, 90.00% and 0.968, respectively. These results demonstrated that the combination of plasma cfDNA concentration, integrity and tumor markers could significantly improve the diagnostic accuracy of NSCLC.Conclusion: Combination of plasma cfDNA concentration, integrity and tumor markers is a promising biomarker for early diagnosis of NSCLC."

基金机构：Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau) [2022QNXM036]

基金资助正文：This work was supported by the Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau) (No. 2022QNXM036) .